|
ES2887254T3
(es)
*
|
2013-03-08 |
2021-12-22 |
Novartis Ag |
Lípidos y composiciones lipídicas para el suministro de agentes activos
|
|
WO2015050871A2
(en)
|
2013-10-04 |
2015-04-09 |
Novartis Ag |
Organic compounds to treat hepatitis b virus
|
|
WO2015051366A2
(en)
|
2013-10-04 |
2015-04-09 |
Novartis Ag |
Novel formats for organic compounds for use in rna interference
|
|
EP3722277A3
(en)
|
2013-10-04 |
2021-01-20 |
Novartis AG |
3'end caps for rna-interferring agents for use in rna
|
|
JP2017500865A
(ja)
*
|
2013-12-19 |
2017-01-12 |
ノバルティス アーゲー |
レプチンｍＲＮＡの組成物および製剤
|
|
HRP20220070T1
(hr)
|
2014-04-23 |
2022-04-01 |
Modernatx, Inc. |
Cjepiva nukleinske kiseline
|
|
CN106794141B
(zh)
*
|
2014-07-16 |
2021-05-28 |
诺华股份有限公司 |
将核酸包封在脂质纳米粒主体中的方法
|
|
EP3200792A4
(en)
*
|
2014-10-03 |
2018-05-09 |
The Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center |
Poly (adp-ribose) polymerase 1 inhibitors structurally unrelated to nad
|
|
US10792299B2
(en)
|
2014-12-26 |
2020-10-06 |
Nitto Denko Corporation |
Methods and compositions for treating malignant tumors associated with kras mutation
|
|
US10264976B2
(en)
*
|
2014-12-26 |
2019-04-23 |
The University Of Akron |
Biocompatible flavonoid compounds for organelle and cell imaging
|
|
US20180002702A1
(en)
|
2014-12-26 |
2018-01-04 |
Nitto Denko Corporation |
Methods and compositions for treating malignant tumors associated with kras mutation
|
|
MA42502A
(fr)
|
2015-07-21 |
2018-05-30 |
Modernatx Inc |
Vaccins contre une maladie infectieuse
|
|
EP3328394A4
(en)
*
|
2015-07-30 |
2019-03-13 |
ModernaTX, Inc. |
CONCATEMEE peptide epitope RNAs
|
|
JP6116782B1
(ja)
|
2015-08-28 |
2017-04-19 |
積水メディカル株式会社 |
ベンジル化合物
|
|
GB201518172D0
(en)
*
|
2015-10-14 |
2015-11-25 |
Cantab Biopharmaceuticals Patents Ltd |
Colloidal particles for use in medicine
|
|
DE20164728T1
(de)
|
2015-10-22 |
2021-09-30 |
Modernatx, Inc. |
Impfstoffe gegen atemwegsvirus
|
|
SG11201803360UA
(en)
*
|
2015-10-22 |
2018-05-30 |
Modernatx Inc |
Nucleic acid vaccines for varicella zoster virus (vzv)
|
|
EP3364949A4
(en)
|
2015-10-22 |
2019-07-31 |
ModernaTX, Inc. |
CANCER VACCINES
|
|
WO2018081480A1
(en)
|
2016-10-26 |
2018-05-03 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
CN108368028B
(zh)
|
2015-10-28 |
2021-09-03 |
爱康泰生治疗公司 |
用于递送核酸的新型脂质和脂质纳米颗粒制剂
|
|
MX2018007987A
(es)
|
2015-12-28 |
2019-01-10 |
Novartis Ag |
Composiciones y metodos para el tratamiento de hemoglobinopatias.
|
|
US12678515B2
(en)
|
2015-12-30 |
2026-07-14 |
Acuitas Therapeutics, Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
ES3030658T3
(en)
*
|
2016-03-30 |
2025-07-01 |
Intellia Therapeutics Inc |
Lipid nanoparticle formulations for crispr/cas components
|
|
JP2019515914A
(ja)
|
2016-04-22 |
2019-06-13 |
インテリア セラピューティクス，インコーポレイテッド |
転写因子４内のトリヌクレオチドリピートと関連する疾患の治療のための組成物および方法
|
|
CA3024509A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Mrna combination therapy for the treatment of cancer
|
|
PL3458083T3
(pl)
|
2016-05-18 |
2023-03-13 |
Modernatx, Inc. |
Polinukleotydy kodujące interleukinę-12 (il12) i ich zastosowania
|
|
WO2017208191A1
(en)
|
2016-06-02 |
2017-12-07 |
Glaxosmithkline Biologicals Sa |
Zika viral antigen constructs
|
|
CN109562153A
(zh)
*
|
2016-08-07 |
2019-04-02 |
诺华股份有限公司 |
mRNA介导的免疫方法
|
|
WO2018060288A1
(en)
|
2016-09-29 |
2018-04-05 |
Glaxosmithkline Biologicals S.A. |
Compositions and methods of treatment of persistent hpv infection
|
|
GB201616904D0
(en)
|
2016-10-05 |
2016-11-16 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
MA46766A
(fr)
|
2016-11-11 |
2019-09-18 |
Modernatx Inc |
Vaccin antigrippal
|
|
EP3541416A1
(en)
|
2016-11-17 |
2019-09-25 |
GlaxoSmithKline Biologicals SA |
Zika viral antigen constructs
|
|
CN110198707A
(zh)
*
|
2016-11-28 |
2019-09-03 |
赛力克斯生物私人有限公司 |
用于治疗口腔感染性疾病的组合物和方法
|
|
JP7383478B2
(ja)
*
|
2016-12-22 |
2023-11-20 |
インテリア セラピューティクス，インコーポレイテッド |
アルファ１アンチトリプシン欠乏症を治療するための組成物および方法
|
|
CA3048485C
(en)
*
|
2016-12-26 |
2022-07-19 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of chronic pain
|
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
|
WO2018170260A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Respiratory syncytial virus vaccine
|
|
US11576961B2
(en)
|
2017-03-15 |
2023-02-14 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
MA48047A
(fr)
|
2017-04-05 |
2020-02-12 |
Modernatx Inc |
Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
|
|
EP3461497A1
(en)
|
2017-09-27 |
2019-04-03 |
GlaxoSmithKline Biologicals S.A. |
Viral antigens
|
|
TWI904069B
(zh)
|
2017-09-29 |
2025-11-11 |
美商英特利亞醫療公司 |
用於ttr基因編輯及治療attr澱粉樣變性之組合物及方法
|
|
EP3688162B1
(en)
|
2017-09-29 |
2024-03-06 |
Intellia Therapeutics, Inc. |
Formulations
|
|
IL311278B2
(en)
|
2017-09-29 |
2026-05-01 |
Intellia Therapeutics Inc |
Polynucleotides, compositions, and methods for genome editing
|
|
CA3077391A1
(en)
|
2017-09-29 |
2019-04-04 |
Intellia Therapeutics, Inc. |
In vitro method of mrna delivery using lipid nanoparticles
|
|
US11911453B2
(en)
|
2018-01-29 |
2024-02-27 |
Modernatx, Inc. |
RSV RNA vaccines
|
|
AU2019321186B2
(en)
|
2018-08-17 |
2024-05-23 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions and uses thereof
|
|
MX2021003455A
(es)
*
|
2018-10-02 |
2021-09-21 |
Intellia Therapeutics Inc |
Lípidos con amina ionizables.
|
|
CA3116132A1
(en)
|
2018-10-16 |
2020-04-23 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunotherapy
|
|
BR112021007343A2
(pt)
|
2018-10-18 |
2021-08-03 |
Intellia Therapeutics, Inc. |
composições e métodos para expressão de transgene a partir de um lócus de albumina
|
|
CA3116576A1
(en)
|
2018-10-18 |
2020-04-23 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
JP7578590B2
(ja)
|
2018-10-18 |
2024-11-06 |
インテリア セラピューティクス，インコーポレーテッド |
第ｉｘ因子を発現するための組成物及び方法
|
|
MX2021004276A
(es)
|
2018-10-18 |
2021-09-08 |
Intellia Therapeutics Inc |
Composiciones y metodos para tratar deficiencia de alfa-1 antitripsina.
|
|
CN113272428A
(zh)
|
2018-10-18 |
2021-08-17 |
英特利亚治疗股份有限公司 |
核酸构建体和使用方法
|
|
CN119285480A
(zh)
|
2018-12-05 |
2025-01-10 |
英特利亚治疗股份有限公司 |
改性的胺脂质
|
|
MA55321A
(fr)
|
2019-03-15 |
2022-01-19 |
Modernatx Inc |
Vaccins à base d'arn contre le vih
|
|
KR20220004648A
(ko)
|
2019-03-28 |
2022-01-11 |
인텔리아 테라퓨틱스, 인크. |
Ttr 가이드 rna, 및 rna-가이드 dna 결합제를 암호화하는 폴리뉴클레오티드를 포함하는 조성물 및 방법
|
|
MX2021011757A
(es)
|
2019-03-28 |
2021-12-10 |
Intellia Therapeutics Inc |
Polinucleótidos, composiciones y métodos para la expresión de polipéptidos.
|
|
MX2021011690A
(es)
|
2019-03-28 |
2022-01-06 |
Intellia Therapeutics Inc |
Composiciones y métodos para la edición del gen ttr y el tratamiento de la amiloidosis attr que comprende un corticosteroide o uso de este.
|
|
WO2020219876A1
(en)
|
2019-04-25 |
2020-10-29 |
Intellia Therapeutics, Inc. |
Ionizable amine lipids and lipid nanoparticles
|
|
US20220259617A1
(en)
|
2019-06-13 |
2022-08-18 |
The General Hospital Corporation |
Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
|
|
CA3147875A1
(en)
|
2019-07-19 |
2021-01-28 |
Flagship Pioneering Innovations Vi, Llc |
Recombinase compositions and methods of use
|
|
MX2022000879A
(es)
|
2019-07-21 |
2022-05-02 |
Glaxosmithkline Biologicals Sa |
Vacuna viral terapeutica.
|
|
JP7600208B2
(ja)
|
2019-07-29 |
2024-12-16 |
ジョージア テック リサーチ コーポレイション |
拘束された脂質を含むナノ材料およびその使用
|
|
CA3146607A1
(en)
|
2019-09-01 |
2021-03-04 |
Joseph Yeshayahu KLEIN |
Cannabinoid containing targeting liposomes
|
|
MX2022006854A
(es)
|
2019-12-04 |
2022-11-30 |
Orna Therapeutics Inc |
Composiciones y metodos de arn circular.
|
|
JP7846007B2
(ja)
|
2019-12-18 |
2026-04-14 |
ノバルティス アーゲー |
異常ヘモグロビン症の治療用組成物及び方法
|
|
CN115175894B
(zh)
|
2020-01-09 |
2024-09-06 |
盖德治疗有限责任公司 |
纳米材料
|
|
BR112022017715A2
(pt)
|
2020-03-04 |
2022-11-16 |
Flagship Pioneering Innovations Vi Llc |
Métodos e composições para modular um genoma
|
|
US20230364219A1
(en)
|
2020-04-16 |
2023-11-16 |
Glaxosmithkline Biologicals Sa |
Sars cov-2 spike protein construct
|
|
KR20230017783A
(ko)
|
2020-04-28 |
2023-02-06 |
인텔리아 테라퓨틱스, 인크. |
시험관내 세포 전달 방법
|
|
IL298363A
(en)
|
2020-05-20 |
2023-01-01 |
Flagship Pioneering Innovations Vi Llc |
Immunogenic compositions and uses thereof
|
|
AU2021275223A1
(en)
|
2020-05-20 |
2023-02-02 |
Flagship Pioneering Innovations Vi, Llc. |
Coronavirus antigen compositions and their uses
|
|
MX2022014606A
(es)
|
2020-05-22 |
2023-03-08 |
Wave Life Sciences Ltd |
Composiciones de oligonucleótidos bicatenarios y métodos relacionados con las mismas.
|
|
US20230203510A1
(en)
|
2020-05-29 |
2023-06-29 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods relating thereto
|
|
EP4158032A2
(en)
|
2020-05-29 |
2023-04-05 |
Flagship Pioneering Innovations VI, LLC |
Trem compositions and methods relating thereto
|
|
WO2021245611A1
(en)
|
2020-06-05 |
2021-12-09 |
Glaxosmithkline Biologicals Sa |
Modified betacoronavirus spike proteins
|
|
EP4171629A1
(en)
|
2020-06-29 |
2023-05-03 |
GlaxoSmithKline Biologicals S.A. |
Adjuvants
|
|
KR20230051172A
(ko)
|
2020-07-16 |
2023-04-17 |
아퀴타스 테라퓨틱스 인크. |
지질 나노 입자에 사용하기 위한 양이온성 지질
|
|
BR112023001272A2
(pt)
|
2020-07-24 |
2023-04-04 |
Massachusetts Gen Hospital |
Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
|
|
IL300947A
(en)
|
2020-09-03 |
2023-04-01 |
Flagship Pioneering Innovations Vi Llc |
Immunogenic compositions and uses thereof
|
|
WO2022056273A1
(en)
*
|
2020-09-11 |
2022-03-17 |
Arrowhead Pharmaceuticals, Inc. |
Lipid conjugates for the delivery of therapeutic agents
|
|
WO2022060871A1
(en)
|
2020-09-15 |
2022-03-24 |
Verve Therapeutics, Inc. |
Lipid formulations for gene editing
|
|
CZ310613B6
(cs)
*
|
2020-09-23 |
2026-01-28 |
Ústav organické chemie a biochemie AV ČR, v. v. i. |
Lipidoidy pro transfekci nukleových kyselin a jejich použití
|
|
CN117098541A
(zh)
|
2020-11-25 |
2023-11-21 |
阿卡格拉医药公司 |
用于递送核酸的脂质纳米粒及相关使用方法
|
|
WO2022112855A1
(en)
*
|
2020-11-27 |
2022-06-02 |
Guangzhou Ribobio Co., Ltd |
Lipid compound and the composition thereof
|
|
EP4259792A1
(en)
|
2020-12-11 |
2023-10-18 |
Intellia Therapeutics, Inc. |
Polynucleotides, compositions, and methods for genome editing involving deamination
|
|
US20240301006A1
(en)
|
2020-12-23 |
2024-09-12 |
Glaxosmithkline Biologicals Sa |
Self-amplifying messenger rna
|
|
KR20230135585A
(ko)
|
2020-12-23 |
2023-09-25 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
변형된 trem의 조성물 및 이의 용도
|
|
JP2024502036A
(ja)
|
2020-12-30 |
2024-01-17 |
インテリア セラピューティクス，インコーポレイテッド |
操作されたｔ細胞
|
|
EP4281080A4
(en)
|
2021-01-20 |
2025-09-24 |
Beam Therapeutics Inc |
NANOMATERIALS COMPRISING A BIODEGRADABLE ELEMENT
|
|
CA3203741A1
(en)
*
|
2021-01-20 |
2022-07-28 |
Beam Therapeutics Inc. |
Nanomaterials comprising an ionizable lipid
|
|
CN116761888A
(zh)
|
2021-01-20 |
2023-09-15 |
比姆医疗股份有限公司 |
纳米材料
|
|
EP4032546A1
(en)
|
2021-01-20 |
2022-07-27 |
GlaxoSmithKline Biologicals S.A. |
Therapeutic viral vaccine
|
|
CN112961065B
(zh)
*
|
2021-02-05 |
2023-03-14 |
嘉晨西海(杭州)生物技术有限公司 |
一种可电离脂质分子及其制备方法及其在制备脂质纳米颗粒的应用
|
|
EP4313152A1
(en)
|
2021-03-26 |
2024-02-07 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic compositions
|
|
EP4313109A1
(en)
|
2021-03-31 |
2024-02-07 |
Flagship Pioneering Innovations V, Inc. |
Thanotransmission polypeptides and their use in treating cancer
|
|
WO2022215758A1
(ja)
|
2021-04-09 |
2022-10-13 |
相互薬工株式会社 |
脂質および組成物
|
|
EP4322920A1
(en)
|
2021-04-17 |
2024-02-21 |
Intellia Therapeutics, Inc. |
Lipid nanoparticle compositions
|
|
CA3216873A1
(en)
|
2021-04-17 |
2022-10-22 |
Intellia Therapeutics, Inc. |
Lipid nanoparticle compositions
|
|
US20240300977A1
(en)
|
2021-04-17 |
2024-09-12 |
Intellia Therapeutics, Inc. |
Inhibitors of dna-dependent protein kinase and compositions and uses thereof
|
|
US20240285755A1
(en)
|
2021-05-24 |
2024-08-29 |
Glaxosmithkline Biologicals Sa |
Adjuvants
|
|
CN119233964A
(zh)
*
|
2021-05-24 |
2024-12-31 |
宾夕法尼亚大学理事会 |
核酸的单组分递送系统
|
|
WO2022259191A1
(en)
|
2021-06-09 |
2022-12-15 |
Glaxosmithkline Biologicals Sa |
Release assay for determining potency of self-amplifying rna drug product and methods for using
|
|
TW202317764A
(zh)
|
2021-06-10 |
2023-05-01 |
美商英特利亞醫療公司 |
用於基因編輯之包含內部連接子之經修飾引導rna
|
|
US20250127809A1
(en)
|
2021-06-23 |
2025-04-24 |
Novartis Ag |
Compositions and methods for the treatment of hemoglobinopathies
|
|
WO2023009547A1
(en)
|
2021-07-26 |
2023-02-02 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and uses thereof
|
|
US20250134824A1
(en)
|
2021-08-16 |
2025-05-01 |
Glaxosmithkline Biologicals Sa |
Low-dose lyophilized rna vaccines and methods for preparing and using the same
|
|
US20240350410A1
(en)
|
2021-08-16 |
2024-10-24 |
Glaxosmithkline Biologicals Sa |
Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
|
|
WO2023020993A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
WO2023020992A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
WO2023020994A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
WO2023031855A1
(en)
|
2021-09-03 |
2023-03-09 |
Glaxosmithkline Biologicals Sa |
Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids
|
|
KR20260037664A
(ko)
|
2021-09-08 |
2026-03-18 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
게놈을 조절하기 위한 방법 및 조성물
|
|
AR127073A1
(es)
|
2021-09-17 |
2023-12-13 |
Flagship Pioneering Innovations Vi Llc |
Composiciones y métodos para producir polirribonucleótidos circulares
|
|
EP4419706A1
(en)
|
2021-10-18 |
2024-08-28 |
Flagship Pioneering Innovations VI, LLC |
Compositions and methods for purifying polyribonucleotides
|
|
EP4423271A2
(en)
|
2021-10-28 |
2024-09-04 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-related methods and compositions for knocking out c5
|
|
EP4426822A2
(en)
|
2021-11-03 |
2024-09-11 |
Intellia Therapeutics, Inc. |
Polynucleotides, compositions, and methods for genome editing
|
|
WO2023081526A1
(en)
|
2021-11-08 |
2023-05-11 |
Orna Therapeutics, Inc. |
Lipid nanoparticle compositions for delivering circular polynucleotides
|
|
IL312965A
(en)
|
2021-11-24 |
2024-07-01 |
Flagship Pioneering Innovations Vi Llc |
Immunogenic compositions and their uses
|
|
MX2024006407A
(es)
|
2021-11-24 |
2024-08-19 |
Flagship Pioneering Innovations Vi Llc |
Composiciones de inmunogenos del virus varicela-zoster y sus usos.
|
|
WO2023096990A1
(en)
|
2021-11-24 |
2023-06-01 |
Flagship Pioneering Innovation Vi, Llc |
Coronavirus immunogen compositions and their uses
|
|
WO2023102364A1
(en)
*
|
2021-12-02 |
2023-06-08 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Antiviral compounds, compositions and uses thereof
|
|
US20250223584A2
(en)
|
2021-12-03 |
2025-07-10 |
The Broad Institute, Inc. |
Compositions and methods for efficient in vivo delivery
|
|
EP4453201A1
(en)
|
2021-12-22 |
2024-10-30 |
Flagship Pioneering Innovations VI, LLC |
Compositions and methods for purifying polyribonucleotides
|
|
AU2022420620A1
(en)
|
2021-12-23 |
2024-07-04 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
WO2023148303A1
(de)
*
|
2022-02-02 |
2023-08-10 |
Mslsolutions Gmbh |
Verfahren zur medikament- und impfstoffherstellung
|
|
IL314482A
(en)
|
2022-02-02 |
2024-09-01 |
Regeneron Pharma |
Anti-tfr:gaa and anti-cd63:gaa insertions for treatment of pompe disease
|
|
JP7894574B2
(ja)
*
|
2022-03-07 |
2026-07-24 |
スペラファーマ株式会社 |
ペプチド合成方法
|
|
WO2023178065A2
(en)
*
|
2022-03-15 |
2023-09-21 |
Broadpharm Inc. |
Lipid compounds and lipid nanoparticles
|
|
CA3245624A1
(en)
*
|
2022-03-25 |
2023-09-28 |
Sail Biomedicines, Inc. |
NEW IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND THEIR METHODS OF USE
|
|
JP2025511756A
(ja)
|
2022-04-08 |
2025-04-16 |
フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー |
ワクチン及び関連する方法
|
|
AU2023269134A1
(en)
|
2022-05-09 |
2024-12-12 |
Regeneron Pharmaceuticals, Inc. |
Vectors and methods for in vivo antibody production
|
|
WO2023220083A1
(en)
|
2022-05-09 |
2023-11-16 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods of use for treating proliferative disorders
|
|
JP2025516638A
(ja)
|
2022-05-13 |
2025-05-30 |
フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー |
二本鎖ｄｎａ組成物及び関連する方法
|
|
JP2025519070A
(ja)
|
2022-05-17 |
2025-06-24 |
エンヴェロップ セラピューティクス， インコーポレイテッド |
効率的ｉｎ ｖｉｖｏ送達のための組成物および方法
|
|
CN119384498A
(zh)
|
2022-06-16 |
2025-01-28 |
因特利亚治疗公司 |
用于对细胞进行遗传修饰的方法和组合物
|
|
WO2023242817A2
(en)
|
2022-06-18 |
2023-12-21 |
Glaxosmithkline Biologicals Sa |
Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2
|
|
EP4544043A1
(en)
|
2022-06-22 |
2025-04-30 |
Flagship Pioneering Innovations VI, LLC |
Compositions of modified trems and uses thereof
|
|
WO2024006955A1
(en)
|
2022-06-29 |
2024-01-04 |
Intellia Therapeutics, Inc. |
Engineered t cells
|
|
CN115286523B
(zh)
*
|
2022-07-15 |
2024-03-19 |
中国科学院基础医学与肿瘤研究所(筹) |
用于递送活性成分的脂质分子及其组合物的制备和应用
|
|
EP4540222A1
(en)
|
2022-07-20 |
2025-04-23 |
Beam Therapeutics Inc. |
Nanomaterials comprising triols
|
|
CN120659627A
(zh)
|
2022-07-29 |
2025-09-16 |
瑞泽恩制药公司 |
用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法
|
|
US20240042021A1
(en)
|
2022-08-01 |
2024-02-08 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory proteins and related methods
|
|
EP4569112A1
(en)
|
2022-08-12 |
2025-06-18 |
Remix Therapeutics Inc. |
Methods and compositions for modulating splicing at alternative splice sites
|
|
CA3267272A1
(en)
|
2022-09-26 |
2024-04-04 |
Glaxosmithkline Biologicals Sa |
FLU VIRUS VACCINES
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
EP4612296A1
(en)
|
2022-10-31 |
2025-09-10 |
Flagship Pioneering Innovations VI, LLC |
Compositions and methods for purifying polyribonucleotides
|
|
AU2023371614A1
(en)
|
2022-11-04 |
2025-05-15 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
|
WO2024102799A1
(en)
|
2022-11-08 |
2024-05-16 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for producing circular polyribonucleotides
|
|
TW202428289A
(zh)
|
2022-11-08 |
2024-07-16 |
美商歐納醫療公司 |
環狀rna組合物
|
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
|
AU2023379457A1
(en)
|
2022-11-14 |
2025-05-15 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
|
TW202430215A
(zh)
|
2022-12-14 |
2024-08-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
用於將治療劑遞送至骨之組成物和方法
|
|
EP4634390A2
(en)
|
2022-12-15 |
2025-10-22 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
WO2024133160A1
(en)
|
2022-12-19 |
2024-06-27 |
Glaxosmithkline Biologicals Sa |
Hepatitis b compositions
|
|
EP4638783A2
(en)
|
2022-12-22 |
2025-10-29 |
Intellia Therapeutics, Inc. |
Methods for analyzing nucleic acid cargos of lipid nucleic acid assemblies
|
|
CN120418427A
(zh)
|
2022-12-23 |
2025-08-01 |
因特利亚治疗公司 |
用于基因组编辑的系统和方法
|
|
US20240252520A1
(en)
|
2023-01-09 |
2024-08-01 |
Beth Israel Deaconess Medical Center, Inc. |
Therapeutic agents and their use for treating chronic wounds
|
|
EP4648794A2
(en)
|
2023-01-09 |
2025-11-19 |
Flagship Pioneering Innovations VII, LLC |
Vaccines and related methods
|
|
US20240238473A1
(en)
|
2023-01-09 |
2024-07-18 |
Beth Israel Deaconess Medical Center, Inc. |
Recombinant nucleic acid molecules and their use in wound healing
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
WO2024160936A1
(en)
|
2023-02-03 |
2024-08-08 |
Glaxosmithkline Biologicals Sa |
Rna formulation
|
|
TW202438515A
(zh)
|
2023-02-06 |
2024-10-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
免疫調節組合物及相關方法
|
|
US20240293318A1
(en)
|
2023-02-13 |
2024-09-05 |
Flagship Pioneering Innovations Vii, Llc |
Cleavable linker-containing ionizable lipids and lipid carriers for therapeutic compositions
|
|
GB202302092D0
(en)
|
2023-02-14 |
2023-03-29 |
Glaxosmithkline Biologicals Sa |
Analytical method
|
|
KR20250151437A
(ko)
|
2023-02-17 |
2025-10-21 |
플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 |
변형된 우라실을 포함하는 dna 조성물
|
|
TW202446956A
(zh)
|
2023-02-17 |
2024-12-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
包含經修飾的胞嘧啶的ｄｎａ組成物
|
|
EP4680750A1
(en)
|
2023-03-15 |
2026-01-21 |
Flagship Pioneering Innovations VI, LLC |
Compositions comprising polyribonucleotides and uses thereof
|
|
EP4680276A1
(en)
|
2023-03-15 |
2026-01-21 |
Flagship Pioneering Innovations VI, LLC |
Immunogenic compositions and uses thereof
|
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
AU2024255972A1
(en)
|
2023-04-12 |
2025-10-23 |
Flagship Pioneering Innovations Vi, Llc |
Modified trems, compositions, and related methods thereof
|
|
WO2024216128A1
(en)
|
2023-04-12 |
2024-10-17 |
Flagship Pioneering Innovations Vi, Llc |
Trems for use in correction of missense mutations
|
|
WO2024220746A2
(en)
|
2023-04-21 |
2024-10-24 |
Flagship Pioneering Innovations Vii, Llc |
Rnai agents targeting fatty acid synthase and related methods
|
|
JP2026518411A
(ja)
|
2023-04-27 |
2026-06-08 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
インフルエンザウイルスワクチン
|
|
EP4701657A1
(en)
|
2023-04-27 |
2026-03-04 |
GlaxoSmithKline Biologicals S.A. |
Influenza virus vaccines
|
|
WO2024233308A2
(en)
|
2023-05-05 |
2024-11-14 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
TW202502729A
(zh)
|
2023-05-19 |
2025-01-16 |
美商英特利亞醫療公司 |
可電離胺脂質
|
|
WO2024258829A1
(en)
|
2023-06-12 |
2024-12-19 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
WO2025006684A1
(en)
|
2023-06-28 |
2025-01-02 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
CN116535381B
(zh)
*
|
2023-07-06 |
2023-10-17 |
北京悦康科创医药科技股份有限公司 |
具有五元环缩醛结构的阳离子脂质化合物、包含其的组合物及用途
|
|
CN121532514A
(zh)
|
2023-07-07 |
2026-02-13 |
上海环码生物医药有限公司 |
用于季节性流感的环状rna疫苗及使用方法
|
|
KR20260044217A
(ko)
|
2023-07-25 |
2026-04-01 |
플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 |
Cas 엔도뉴클레아제 및 관련 방법
|
|
AR133384A1
(es)
|
2023-07-28 |
2025-09-24 |
Regeneron Pharma |
Anti-tfr:esfingomielinasa ácida para el tratamiento de la deficiencia de esfingomielinasa ácida
|
|
AU2024315073A1
(en)
|
2023-07-28 |
2026-01-22 |
Regeneron Pharmaceuticals, Inc. |
Use of bgh-sv40l tandem polya to enhance transgene expression during unidirectional gene insertion
|
|
WO2025042786A1
(en)
|
2023-08-18 |
2025-02-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising circular polyribonucleotides and uses thereof
|
|
WO2025049481A1
(en)
|
2023-08-28 |
2025-03-06 |
Intellia Therapeutics, Inc. |
Methods of editing an hla-a gene in vitro
|
|
EP4771042A1
(en)
|
2023-08-29 |
2026-07-08 |
Shanghai Circode Biomed Co., Ltd |
Circular rna encoding vegf polypeptides, formulations, and methods of uses
|
|
WO2025054236A2
(en)
|
2023-09-06 |
2025-03-13 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
IL327035A
(en)
|
2023-09-18 |
2026-05-01 |
Flagship Pioneering Innovations Vii Llc |
Ionizable lipidoid compositions and their medical uses
|
|
WO2025072331A1
(en)
|
2023-09-26 |
2025-04-03 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025096807A2
(en)
|
2023-10-31 |
2025-05-08 |
Flagship Pioneering Innovations Vii, Llc |
Novel therapeutic dna forms
|
|
CN122497525A
(zh)
|
2023-11-07 |
2026-07-31 |
欧纳医疗公司 |
环状rna组合物
|
|
KR20260113064A
(ko)
|
2023-11-14 |
2026-07-21 |
플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 |
이온화 가능한 리피도이드 조성물 및 이의 치료적 용도
|
|
US20250161347A1
(en)
|
2023-11-22 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Methods and compositions for treating non-alcoholic fatty liver disease
|
|
WO2025117732A1
(en)
*
|
2023-11-29 |
2025-06-05 |
Akagera Medicines, Inc. |
Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
|
|
WO2025117877A2
(en)
|
2023-12-01 |
2025-06-05 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025137301A1
(en)
|
2023-12-20 |
2025-06-26 |
Intellia Therapeutics, Inc. |
Methods for rapid engineering of cells
|
|
IL330230A
(en)
|
2023-12-20 |
2026-08-01 |
Intellia Therapeutics Inc |
Engineered T cells
|
|
WO2025132839A1
(en)
|
2023-12-21 |
2025-06-26 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
US20250375499A1
(en)
|
2024-01-26 |
2025-12-11 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025160340A2
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
WO2025194019A1
(en)
|
2024-03-14 |
2025-09-18 |
Flagship Pioneering Innovations Vii, Llc |
Methods for treating liver fibrosis and non-alcoholic fatty liver disease
|
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|
|
WO2025217275A2
(en)
|
2024-04-10 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Immune cell targeted compositions and related methods
|
|
WO2025229572A1
(en)
|
2024-05-01 |
2025-11-06 |
Glaxosmithkline Biologicals Sa |
Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines
|
|
TW202613158A
(zh)
|
2024-05-16 |
2026-04-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
免疫受體抑制蛋白及相關方法
|
|
WO2025240946A1
(en)
|
2024-05-17 |
2025-11-20 |
Intellia Therapeutics, Inc. |
Lipid nanoparticles and lipid nanoparticle compositions
|
|
WO2025245188A2
(en)
|
2024-05-21 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Methods of treating liver steatosis and non-alcoholic fatty liver disease
|
|
WO2025245111A1
(en)
|
2024-05-22 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor targeting proteins and related methods
|
|
WO2025265017A1
(en)
|
2024-06-20 |
2025-12-26 |
Regeneron Pharmaceuticals, Inc. |
Ass1 gene insertion for the treatment of citrullinemia type i
|
|
US20260000702A1
(en)
|
2024-06-26 |
2026-01-01 |
Flagship Pioneering Innovations Vii, Llc |
Therapeutic circular dna forms
|
|
WO2026055543A1
(en)
|
2024-09-06 |
2026-03-12 |
Flagship Pioneering Innovations Vii, Llc |
Modified dna compositions and related methods
|
|
WO2026055547A1
(en)
|
2024-09-06 |
2026-03-12 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions and related methods
|
|
WO2026064313A1
(en)
|
2024-09-17 |
2026-03-26 |
Flagship Pioneering Innovations Vii, Llc |
Rna compositions and related methods
|
|
WO2026085300A1
(en)
|
2024-10-16 |
2026-04-23 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods
|
|
WO2026097018A1
(en)
|
2024-11-04 |
2026-05-07 |
Intellia Therapeutics, Inc. |
Polypeptides, polynucleotides, compositions, and methods for genome editing involving chromatin remodelers
|
|
WO2026102108A1
(en)
|
2024-11-07 |
2026-05-15 |
Flagship Pioneering Innovations Vii, Llc |
Dna production methods
|
|
WO2026122747A2
(en)
|
2024-12-05 |
2026-06-11 |
Flagship Pioneering Innovations Vii, Llc |
Novel immunomodulatory proteins and related methods
|
|
WO2026139456A2
(en)
|
2024-12-23 |
2026-07-02 |
Glaxosmithkline Biologicals Sa |
Self-amplifying messenger rna molecules
|
|
WO2026152023A1
(en)
|
2025-01-10 |
2026-07-16 |
Sail Biomedicines, Inc. |
Lipid compounds, lipid nanoparticle compositions and use thereof with polyribonucleotides
|
|
WO2026151879A1
(en)
|
2025-01-10 |
2026-07-16 |
Flagship Pioneering Innovations Vii, Llc |
Vaccine compositions and methods
|
|
WO2026152164A1
(en)
|
2025-01-13 |
2026-07-16 |
Sail Biomedicines, Inc. |
Cd5-targeted lipid nanoparticles encapsulating polyribonucleotides encoding chimeric antigen receptors, and methods to generate car-expressing t cells in vivo
|
|
CN119462481B
(zh)
*
|
2025-01-17 |
2025-04-25 |
北京悦康科创医药科技股份有限公司 |
Sting激活型佐剂脂质、包含其的组合物及用途
|
|
WO2026161677A1
(en)
|
2025-01-24 |
2026-07-30 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods
|
|
WO2026163162A1
(en)
|
2025-01-31 |
2026-08-06 |
Intellia Therapeutics, Inc. |
Enhanced cas9 variants and uses thereof
|